fbpx
Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

Antibiotics for appendicitis – first-line treatment

Written by | 29 Oct 2021

Antibiotics are now an accepted first-line treatment for most people with appendicitis, according to final results of the Comparing Outcomes of antibiotic Drugs and Appendectomy (CODA) trial, and… read more.

Two studies of Remsima SC shows switching to subcutaneous therapy has no impact on treatment for inflammatory bowel disease – Celltrion Healthcare

Written by | 12 Oct 2021

Celltrion Healthcare announced two data sets relating to the use of the subcutaneous formulation of infliximab, Remsima SC (CT-P13 SC), in inflammatory bowel disease (IBD). The first study… read more.

CHMP recommends Qinlock to treat advanced gastrointestinal stromal tumor – Deciphera Pharmaceuticals

Written by | 8 Oct 2021

Deciphera Pharmaceuticals, Inc. announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the approval of Qinlock… read more.

CHMP recommends Qinlock to treat adult patients with advanced gastrointestinal stromal tumor – Deciphera Pharmaceuticals

Written by | 29 Sep 2021

Deciphera Pharmaceuticals, Inc. announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the approval of Qinlock… read more.

Gut bacteria influence brain development

Written by | 11 Sep 2021

Researchers discover biomarkers that indicate early brain injury in extreme premature infants University of Vienna Extremely premature infants are at a high risk for brain damage. Researchers have… read more.

Can gastrointestinal bleeding after heart attack be predicted?

Written by | 6 Sep 2021

Knowing which patients are at higher risk of bleeding complications following a heart attack can help health professionals to take preventative measures. Now researchers at Karolinska have published… read more.

Ultra-processed food intake linked to inflammatory bowel disease

Written by | 26 Aug 2021

Consumption of ultra-processed foods appears to be linked to an increased risk of inflammatory bowel disease (IBD), researchers reported on July 15, 2021 in the BMJ/British Medical Journal…. read more.

Merck Inc provides update on Keytruda indication in third-line gastric cancer in the US

Written by | 11 Jul 2021

Merck announced that the company plans to voluntarily withdraw the U.S. accelerated approval indication for Keytruda for the treatment of patients with recurrent locally advanced or metastatic gastric… read more.

Persistence pays off in the human gut microbiome

Written by | 28 Jun 2021

The human gut microbiome is a complex community of trillions of microbes that are constantly interacting with each other and our bodies. It supports our wellbeing, immune system… read more.

Janssen presents results of first head-to-head study of biologic therapies in patients with moderate to severe Crohn’s disease

Written by | 12 Jun 2021

The Janssen Pharmaceutical Companies of Johnson & Johnson announced efficacy and safety data for Stelara (ustekinumab) in Crohn’s disease (CD) and ulcerative colitis (UC),including data from the SEAVUE… read more.

GA recommends early use of biologics in patients with moderate-to-severe Crohn’s disease

Written by | 3 Jun 2021

Crohn’s disease, a type of inflammatory bowel disease (IBD) that causes inflammation (pain and swelling) in the gastrointestinal tract, can cause daily health problems, frequent hospitalizations and surgery… read more.

FDA approves Keytruda + Herceptin in HER2-positive gastric or gastroesophageal junction adenocarcinoma – Merck Inc.

Written by | 16 May 2021

Merck Inc announced that the FDA has approved Keytruda (pembrolizumab), Merck’s anti-PD-1 therapy, in combination with Herceptin (trastuzumab), fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of patients… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.